Lisa Tostanoski

NIH T32 Postdoctoral Fellow Barouch Laboratory Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center - Harvard Medical School Area 1: SARS-CoV-2 Pathogenesis and Vaccine Development Projects • Led small animal studies (40+) in collaboration with academic, industry, and foundation partners; spanned study coordination and technical lead on mouse studies, study coordination with CRO team for hamster studies • Analyzed, compiled, and presented data to collaborators on update calls as well as to formal external audiences (e.g., NIH working group, WHO symposium); studies led to 10 published peer-reviewed manuscripts thus far • Co-developed binding antibody (ELISA) assays for non-human primates and human biorepository samples, including a GCLP-compliant assay used in a Phase I clinical trial • Assay development and execution led to co-authorship on 12 peer-reviewed publications; data supported application to the FDA for EUA Area 2: Immune Engineering Projects • Developed degradable, delayed release microparticles towards the goal of mimicking a traditional prime + boost vaccine regimen with a single shot in collaboration with the Jaklenec and Langer groups at MIT • Executed iterative particle fabrication and analysis towards the goal of optimizing the stability of vaccine cargos when filled and dried into the particle core, as well as during controlled release • Additional collaborative projects: multimerization of antigens for low-cost vaccine production, stabilization of mRNA vaccines in delivery platforms (e.g., microneedles), exploration of intrinsic inflammatory properties of carrier systems

National Science Foundation (NSF) Graduate Research Fellow, Ph.D. Candidate (08/2012-09/2017) Postdoctoral Researcher (09/2017-12/2017) Jewell Research Lab Fischell Department of Bioengineering • Led two biomaterials-based projects towards the goal of effective and selective control of autoimmunity • Fabricated degradable polymer particles for direct injection to lymph nodes to study how localized, controlled release of self-antigen and/or small molecules reprograms both local and systemic immune cell function • Demonstrated that a single intra-lymph node injection reverses disease-induced paralysis and restrains infiltration of CD4+ T cells to the spinal cord in a mouse model of multiple sclerosis (EAE) • Engineered directed self-assembly of antigen and an anti-inflammatory nucleic acid (GpG, TLR9 antagonist) into microcapsules composed entirely of immune cues (iPEMs) with tunable absolute and relative cargo loading • Demonstrated that iPEMs restrain inflammatory signaling and skew immune cell phenotype in three systems: primary mouse cells, a mouse model of MS (EAE), samples from a cohort of human MS patients • Presented findings at 7 national and international conferences, published 20 papers (6 first-author), contributed to multiple collaborative projects in the Jewell Lab and with external partners, and mentored 5 junior researchers

Research Intern 2011-2012 (summers).